ASBMR Three Year Pre-Meeting Symposia

美国骨与矿物质研究学会 (ASBMR)，最大的专业、科学和医学协会 成立协会的目的是将参与研究的临床和实验室科学家聚集在一起 骨骼、矿物质和肌肉骨骼科学，拥有举办年度专题会议的成功历史 自 2002 年以来，ASBMR 一直由 NIH R13 年度拨款资助。最近，ASBMR 获得了两次、三年期的 R13 拨款 涵盖 2016-2018 年和 2019-2021 年的会前研讨会计划。目前的申请寻求资金 获得为期三年的 R13 拨款，重点关注三个特定领域，推进肌肉骨骼疾病领域的发展 2022年、2023年和2024年的科学研究：1）“罕见疾病：从分子和机制到 治疗”； 2）“骨细胞在骨骼健康和疾病中的作用以及作为治疗靶细胞”； 3）“能源 骨骼发育和疾病中的新陈代谢”。这三个研讨会涵盖了高度相关的领域 最近在科学知识和集体方面经历了快速发展的肌肉骨骼研究 导致主要的临床发病、残疾和死亡。 R13 的总体目标是刺激 进一步的进步将通过汇集以下方面来改善肌肉骨骼疾病的患者护理 三个研讨会各自的最佳研究人员。研讨会将回顾每个主题领域的最新技术， 与与会者交换想法，并激发年轻研究人员和知名研究人员之间的互动。 我们将鼓励研讨会与会者参加随后举行的 ASBMR 年会，以获取更多信息 与肌肉骨骼研究人员互动的机会。所有三个研讨会的议程均由 组委会和前两次研讨会的所有发言人均已确认参加。 演讲者包括成熟的和年轻的研究人员、女性和男性，并且，因为大约一半的 ASBMR 成员来自美国以外，还邀请了一些重要的国际演讲者。海报 会议、青年研究者奖颁奖典礼以及每次会议结束时的“聚餐”晚会 计划促进年轻研究人员和更资深的演讲者之间的直接互动。 2022 年， 研讨会将聚集罕见骨病领域的国际专家，讨论潜在骨病的最新进展 机制和治疗方法，为临床医生提供如何识别它们的指导，以及从中吸取的教训 与骨质疏松症等更常见的骨病有直接关系的罕见疾病。 2023 年， 研讨会将回顾骨细胞在骨细胞中作用的基础、转化和临床研究进展。 骨的生物学和病理生理学，以及如何以骨细胞为治疗目标。骨细胞的作用 将讨论机械生物学、激素作用、骨癌和骨细胞内分泌作用。 2024年 研讨会将讨论能量代谢在骨骼发育和发育中的作用的最新进展 疾病；包括缺氧和线粒体介导机制的作用及其参与 骨骼对合成代谢疗法和糖尿病等代谢疾病的反应。

The American Society for Bone and Mineral Research (ASBMR), the largest professional, scientific and medical society established to bring together clinical and laboratory-based scientists who are involved in the study of bone, mineral and musculoskeletal science, has had a successful history of conducting annual topical meetings funded by single year NIH R13 grants since 2002. More recently, ASBMR received two, three-year R13 grants to cover pre-meeting symposia programs for 2016-2018 and 2019-2021. The current application seeks funding for a three-year R13 grant to advance the field of musculoskeletal diseases by focusing on three specific areas of scientific research in 2022, 2023 and 2024: 1) “Rare Diseases: From Molecules and Mechanisms to Therapeutics”; 2) “Osteocytes in Bone Health and Disease and as Therapeutic Target Cells”; 3) “Energy Metabolism in Skeletal Development and Disease”. These three symposia cover highly relevant areas of musculoskeletal research that has recently undergone rapid evolution in scientific knowledge and collectively contribute to major clinical morbidity disability and mortality. The overall objective of this R13 is to stimulate further advances that will result in improved patient care for musculoskeletal diseases by bringing together the best researchers for each of the three symposia. The symposia will review the state of the art in each topic area, exchanging ideas with attendees, and stimulating the interaction between young and established researchers. Symposia attendees will be encouraged to attend the subsequent ASBMR Annual Meetings for additional opportunities to interact with musculoskeletal researchers. Programs for all three symposia were developed by an organizing committee, and all speakers for the first two symposia have confirmed their participation. Presenters include established and young investigators, women and men, and, since about half of ASBMR membership is from outside the US, a number of key international speakers have also been invited. Poster sessions, young investigator award presentations, and at the end of each meeting a “dine-around” evening are planned to promote direct interaction between young investigators and more senior speakers. In 2022, the symposium will gather international experts in rare bone diseases to discuss the latest advances on underlying mechanisms and therapies, provide guidance to clinicians on how to recognize them, and lessons learnt from rare diseases that have direct application to more common bone diseases such as osteoporosis. In 2023, the symposium will review the advances in basic, translational and clinical research on the role of osteocytes in the biology and pathophysiology of bone, and how to target osteocytes with therapeutic goals. The osteocyte role in mechanobiology, hormone actions, cancer in bone and osteocyte endocrine actions will be discussed. The 2024 symposium will discuss the recent advances on the role of energy metabolism in skeletal development and disease; including the role of hypoxia and mitochondria-mediated mechanisms, and its involvement in the response of bone to anabolic therapies and metabolic diseases such as diabetes.